Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation (TPD), developing oral small molecule medicines that selectively eliminate disease-causing proteins. Its pipeline includes KT-621 (STAT6 degrader) in Phase 2b trials for atopic dermatitis and asthma, KT-579 (IRF5 degrader) in Phase 1, and IRAK4 degrader KT-485/SAR447971 partnered with Sanofi. The company also has a CDK2 collaboration with Gilead Sciences.
Q2 FY2026 — expected 2026-09-06
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001193125-26-073395 | EDGAR | 104K words |
| 2025-02-27 | 2024-12-31 | 0000950170-25-028355 | EDGAR | 98K words |
| 2024-02-22 | 2023-12-31 | 0000950170-24-018414 | EDGAR | 107K words |
| 2023-02-23 | 2022-12-31 | 0000950170-23-003935 | EDGAR | — |
| 2022-02-24 | 2021-12-31 | 0000950170-22-001860 | EDGAR | — |
| 2021-03-11 | 2020-12-31 | 0001564590-21-012240 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-05 | 2026-06-30 | 0001193125-26-333849 | EDGAR | 71K words |
| 2025-11-04 | 2025-09-30 | 0001193125-25-263550 | EDGAR | 70K words |
| 2025-08-11 | 2025-06-30 | 0000950170-25-106229 | EDGAR | 70K words |
| 2025-05-09 | 2025-03-31 | 0000950170-25-067498 | EDGAR | 64K words |
| 2024-10-31 | 2024-09-30 | 0000950170-24-119249 | EDGAR | 67K words |
| 2024-08-07 | 2024-06-30 | 0000950170-24-092275 | EDGAR | 67K words |
| 2024-05-02 | 2024-03-31 | 0000950170-24-051567 | EDGAR | 64K words |
| 2023-11-02 | 2023-09-30 | 0000950170-23-057743 | EDGAR | 66K words |
| 2023-08-03 | 2023-06-30 | 0000950170-23-037581 | EDGAR | 66K words |
| 2023-05-04 | 2023-03-31 | 0000950170-23-017462 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0000950170-22-021543 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0000950170-22-015745 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-05 | 0001193125-26-333834 | EDGAR | 3K words |
| 2026-07-27 | 0001193125-26-318078 | EDGAR | 1K words |
| 2026-03-27 | 0001193125-26-129170 | EDGAR | 1K words |
| 2026-02-26 | 0001193125-26-073561 | EDGAR | 21K words |
| 2026-02-26 | 0001193125-26-073386 | EDGAR | 3K words |
| 2026-01-13 | 0001193125-26-011104 | EDGAR | 2K words |
| 2025-12-10 | 0001193125-25-314422 | EDGAR | 1K words |
| 2025-12-08 | 0001193125-25-310670 | EDGAR | 6K words |
| 2025-12-08 | 0001193125-25-310572 | EDGAR | 3K words |
| 2025-11-04 | 0001193125-25-263540 | EDGAR | 3K words |
114 total filings indexed. 86 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001815442 |
| Ticker | KYMR |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.kymeratx.com |
| Listed | 2020-08-21 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/KYMR (~200 tokens, structured JSON with cryptographic provenance)